{"gene":"SERPINA1","run_date":"2026-06-10T07:46:30","timeline":{"discoveries":[{"year":1988,"finding":"SERPINA1/A1AT inhibits neutrophil elastase through an active site centered around Met358 contained within an external stressed loop on the surface of the molecule. Two salt bridges (Glu342-Lys290; Glu263-Lys387) are critical for protein stability; disruption of either causes distinct molecular pathology resulting in reduced serum A1AT levels.","method":"Molecular characterization of protein variants, structural analysis, active-site mutagenesis inference from natural variants","journal":"The American journal of medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — active-site residue identified by structural and biochemical characterization, replicated across multiple variant studies and widely confirmed","pmids":["3289385"],"is_preprint":false},{"year":1993,"finding":"The SERPINA1 gene is expressed in human intestinal enterocytes (villous and crypt) in vivo, and also in Paneth cells where it co-localizes with lysozyme, as demonstrated by in situ hybridization and double-label immunohistochemistry of human jejunum and ileum.","method":"In situ hybridization, double-label immunohistochemistry","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — two orthogonal direct localization methods (in situ hybridization + immunohistochemistry) applied to human tissue in vivo","pmids":["8408656"],"is_preprint":false},{"year":1987,"finding":"Human A1AT is glycosylated on three asparagine residues during secretion. When expressed in yeast, the protein receives core carbohydrate on two or three asparagine residues; the secreted yeast form additionally acquires outer mannose chains (yeast-type), all removable by endoglycosidase H treatment.","method":"Recombinant expression in Saccharomyces cerevisiae, endoglycosidase H treatment, analysis of mnn9 mutant","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct biochemical reconstitution in yeast with enzymatic deglycosylation, single study","pmids":["3315863"],"is_preprint":false},{"year":2002,"finding":"Alpha-1-antitrypsin is produced by the mammary gland (mRNA detected by PCR) and is present in human milk at high concentrations early in lactation. A1AT resists in vitro proteolysis by pepsin and pancreatin and, when present, protects lactoferrin from pancreatin-mediated digestion.","method":"RT-PCR of mammary gland cDNA, ELISA measurement in milk samples, in vitro digestion assay with pepsin/pancreatin","journal":"The American journal of clinical nutrition","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — expression confirmed by PCR plus functional in vitro digestion assay showing protease-protective effect, single lab","pmids":["12324297"],"is_preprint":false},{"year":2014,"finding":"A1AT is actively transcytosed across pulmonary endothelial cells to lung epithelial cells. Uptake involves the classical secretory/Golgi pathway; inhibition of Golgi secretion with tunicamycin increased intracellular A1AT retention but promoted non-classical secretion via microparticles. Polymerized A1AT or cigarette smoke exposure decreased transcytosis.","method":"Confocal time-lapse microscopy, transwell co-culture assays, two-photon intravital microscopy in mice, tunicamycin inhibition","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods including in vivo intravital imaging and in vitro transcytosis assay, single lab","pmids":["24743137"],"is_preprint":false},{"year":2015,"finding":"A1AT uptake by pulmonary endothelial cells is mediated primarily by clathrin-coated vesicles and caveolae, and scavenger receptor class B type I (SR-BI) serves as a key receptor for A1AT endocytosis. SR-BI knockdown, neutralizing antibodies, or ligand competition reduced A1AT uptake by 30–50%. SR-BI null mice showed decreased lung A1AT after systemic administration.","method":"Transmission electron microscopy of gold-labeled A1AT, SR-BI immunoprecipitation, SCARB1 siRNA knockdown, neutralizing antibodies, Scarb1 knockout mice","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — receptor identified by Co-IP and confirmed with multiple orthogonal approaches (KD, neutralizing antibody, KO mice, EM), single lab","pmids":["26092999"],"is_preprint":false},{"year":2014,"finding":"A1AT inhibits active caspase-3 and caspase-8 directly in liver homogenates and in a cell-free system in vitro. Both native and oxidized (elastase-inhibitory-activity-deficient) forms of A1AT were equally effective, indicating that the antiapoptotic effect is independent of elastase inhibitory activity. AAT treatment also reduced ADAM17 (TACE) activity and TNF-α levels in vivo.","method":"Cell-free in vitro caspase activity assays, liver homogenate assays, mouse models of acute liver failure (Jo2, acetaminophen, α-amanitin), native vs. oxidized A1AT comparison","journal":"Hepatology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro caspase inhibition assay plus multiple in vivo disease models with mechanistic readouts, single lab","pmids":["24449466"],"is_preprint":false},{"year":2013,"finding":"TFEB (transcription factor EB), a master regulator of autophagy and lysosomal biogenesis, when delivered by liver-directed gene transfer, reduces toxic Z-SERPINA1 polymer accumulation in hepatocytes. The mechanism involves increased degradation of SERPINA1 polymer in autolysosomes and decreased SERPINA1 monomer expression.","method":"Liver-directed TFEB gene transfer in mouse model of SERPINA1 deficiency, histological and biochemical analysis of polymer levels, apoptosis and fibrosis markers","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic intervention with defined pathway (autophagy/lysosomal) and mechanistic readout in vivo, single lab","pmids":["23584152"],"is_preprint":false},{"year":2016,"finding":"NQO1 (NAD(P)H:quinone oxidoreductase 1) binds SERPINA1 mRNA at its 3'UTR and coding region, and promotes translation of A1AT without affecting mRNA levels. NQO1 silencing decreased polysome loading on SERPINA1 mRNA and reduced A1AT protein levels. NQO1-KO mice had reduced hepatic and serum A1AT and increased neutrophil elastase activity.","method":"Ribonucleoprotein immunoprecipitation (RIP) + microarray, biotin pulldown assay, polysome profiling, luciferase reporter assay, NQO1 siRNA knockdown, NQO1-KO mice","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — RIP, biotin pulldown, polysome profiling, reporter assay, and KO mice all used in one study; multiple orthogonal methods confirm mRNA binding and translational regulation","pmids":["27515817"],"is_preprint":false},{"year":2022,"finding":"The 5'-UTR of the NM_000295.4 SERPINA1 transcript folds into a well-defined multi-helix structural domain that optimizes translation by maintaining accessibility at the translation initiation site. Mutations that disrupted the anchor helix of this domain led to non-native structures that created a stable helix near the initiation site, thereby decreasing translation.","method":"SHAPE (Selective 2'-Hydroxyl Acylation analyzed by Primer Extension) RNA structure probing, systematic mutagenesis of the 5'-UTR, luciferase reporter translation assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — RNA structure determined by SHAPE probing and validated by systematic mutagenesis with functional translation readout, single lab with multiple orthogonal methods","pmids":["36107773"],"is_preprint":false},{"year":2020,"finding":"Z A1AT can form heteropolymers with wild-type M A1AT in vivo. A monoclonal antibody (mAb2H2) was developed that preferentially binds M over Z A1AT; its epitope was localized by crystallography to a region perturbed by the Z (Glu342Lys) substitution. Negative-stain electron microscopy of Fab-labeled polymers from an MZ heterozygote liver explant revealed that M A1AT comprises approximately 6% of polymer subunits in vivo.","method":"Monoclonal antibody epitope mapping by crystallography, negative-stain electron microscopy of Fab-labeled polymers from human liver explant","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure of antibody epitope plus EM of labeled in vivo polymers; direct structural demonstration of heteropolymerization","pmids":["32699193"],"is_preprint":false},{"year":2018,"finding":"Seven novel SERPINA1 missense variants were functionally characterized in HEK293T cells. Variants S+S14F, I50N, A58D, F227C, and T249A formed intracellular polymers and failed to secrete AAT protein. Variant K328E showed intracellular retention and reduced antielastase activity. Variant E151K secreted normally without polymer formation.","method":"Overexpression in HEK293T cells, PAS staining, Western blotting, pulse-chase assay, elastase inhibition assay","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro functional assays with multiple readouts (polymerization, secretion, enzymatic activity) across multiple variants, single lab","pmids":["29232161"],"is_preprint":false},{"year":2017,"finding":"Carbamylated alpha-1-antitrypsin (Ca-A1AT) is an antigenic target of anti-carbamylated protein (anti-CarP) antibodies in rheumatoid arthritis patients. A1AT contains surface-accessible lysines that can be carbamylated, and carbamylated A1AT peptides were identified in synovial fluid of an RA patient by mass spectrometry.","method":"Ion exchange chromatography fractionation of carbamylated FCS, mass spectrometry identification, ELISA with Ca-A1AT, mass spectrometry of synovial fluid","journal":"Journal of autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — protein identified as autoantigen by MS and confirmed by ELISA, with in vivo detection in synovial fluid, single lab","pmids":["28291659"],"is_preprint":false},{"year":2012,"finding":"AAT inhibits NO production in macrophages by suppressing iNOS expression and NF-κB activation, independent of MAPK signaling. AAT reduced intracellular translocation of exogenous AAT in stimulated cells. In vivo, individuals with genetic AAT deficiency had significantly increased exhaled NO compared to healthy controls.","method":"RAW 264.7 cell stimulation assays, NO measurement, iNOS and NF-κB activation assays, MAPK phosphorylation assays, comparison with synthetic serine protease inhibitor CE-2072, exhaled NO measurement in AAT-deficient subjects","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanistic dissection with NF-κB and iNOS readouts plus in vivo human correlation, single lab","pmids":["22975343"],"is_preprint":false},{"year":2017,"finding":"AAT dose-dependently inhibited RANKL-induced osteoclast formation from bone marrow macrophages and RAW264.7 cells. Mechanistically, AAT inhibited M-CSF-induced RANK surface expression on osteoclast precursors, suppressed RANKL-induced TNF-α production, and inhibited DC-STAMP gene expression and CD9 surface expression. AAT treatment significantly inhibited osteoclast-mediated mineral resorption.","method":"In vitro osteoclast differentiation assay, gene expression analysis, RANK surface expression assay, mineral resorption assay","journal":"Molecular medicine (Cambridge, Mass.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic readouts in vitro (receptor expression, gene expression, functional resorption), single lab","pmids":["28332697"],"is_preprint":false},{"year":2021,"finding":"In human chondrocytes, SERPINA1 transfection and recombinant AAT protein promoted chondrogenic differentiation through activation of PKA-dependent CREB signaling and inhibition of Wnt/β-catenin pathways, upregulating col2a1, acan, and sox9 while downregulating mmp13 and adamts5.","method":"SERPINA1 transfection in human chondrocytes, signaling pathway analysis (PKA/CREB, Wnt/β-catenin), gene expression analysis, in vivo arthritis models (KBxN serum, neutrophil elastase)","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro pathway identification with two signaling readouts plus in vivo arthritis models, single lab","pmids":["33788977"],"is_preprint":false},{"year":2020,"finding":"In AATD neutrophils, increased degranulation involves Rac2 activation leading to PAR2 activation by serine proteinases, resulting in enhanced reactive oxygen species production. AAT reduced primary granule release; augmentation therapy in vivo resolved the elevated surface abundance of neutrophil elastase and altered the AATD neutrophil membrane proteome toward that of non-AATD COPD.","method":"Label-free tandem mass spectrometry of neutrophil membrane proteome, Western blot, ELISA, FRET analysis, in vivo augmentation therapy cohort comparison","journal":"The European respiratory journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomics plus multiple orthogonal validation methods and in vivo human cohort; mechanistic pathway (Rac2→PAR2→ROS) identified, single lab","pmids":["32060059"],"is_preprint":false},{"year":2024,"finding":"Hepatocyte-derived SerpinA1/A1AT forms a complex with EphB2 receptor and regulates its downstream signaling in adipocytes, promoting preadipocyte proliferation and increasing UCP1 expression to activate mitochondrial thermogenesis. Liver-specific SerpinA1 transgenic mice showed increased adipose browning, reduced adiposity, and improved glucose tolerance; SerpinA1 KO mice had impaired thermogenesis, obesity, and insulin resistance.","method":"Liver-specific transgenic overexpression, SerpinA1 knockout mice, co-immunoprecipitation (EphB2 complex), gene expression and protein assays in adipocytes, metabolic phenotyping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — receptor binding identified by Co-IP, complementary gain- and loss-of-function mouse models with defined metabolic phenotypes, single lab with multiple orthogonal methods","pmids":["39532838"],"is_preprint":false},{"year":2025,"finding":"In MASH, hepatic IL-1β produced by Kupffer cells transcriptionally inhibits A1AT expression via HNF4α. Loss of A1AT increases activity of proteinase 3 (PR3), which cleaves IL-32γ and converts it from an anti-inflammatory/antifibrogenic cytokine into a KC activator, thereby promoting MASH and fibrosis progression. A1AT restoration or PR3 inhibition mitigated MASH in vivo.","method":"Quintuple Serpina1a-e knockout mice on fast-food diet, IL-1β stimulation, PR3 activity assays, IL-32γ V104A cleavage-resistant mutant, cytokine arrays, in vivo A1AT restoration, transcription factor (HNF4α) analysis","journal":"Experimental & molecular medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — KO mice, cleavage-resistant mutant, transcription factor identification, and in vivo rescue all used; multiple orthogonal methods establishing pathway position, single lab","pmids":["39939782"],"is_preprint":false},{"year":2021,"finding":"siRNA knockdown of SERPINA1 in trophoblast-derived HTR8/SVneo cells markedly affected actin cytoskeleton pathway regulation, Slit-Robo signaling, and extracellular matrix organization. Rare damaging SERPINA1 variants were identified in families with recurrent spontaneous preterm deliveries, and A1AT protein levels were downregulated in placental tissue from spontaneous preterm births.","method":"siRNA knockdown with pathway analysis, whole exome sequencing, placental proteomics and mRNA quantification, immunoelectron microscopy","journal":"BMC medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with defined pathway readouts plus human exome and proteomic data, single lab","pmids":["35477570"],"is_preprint":false},{"year":2017,"finding":"Exogenous A1AT dose-dependently reduced SERPINA1 mRNA expression in primary human hepatocytes (including AAT-deficient patient hepatocytes), an effect potentiated by Oncostatin M. Exogenous A1AT also reduced SERPINA1 expression in human peripheral blood mononuclear cells, suggesting a negative feedback mechanism on its own expression.","method":"Treatment of primary human hepatocytes and PBMCs with purified A1AT, qRT-PCR for SERPINA1 mRNA, dose-response analysis, OSM co-stimulation, analysis of lung tissue from patients on augmentation therapy","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct treatment of primary human cells with dose-response and multiple cell types tested, single lab","pmids":["28486562"],"is_preprint":false}],"current_model":"SERPINA1/A1AT is a 52-kDa hepatocyte-derived serine protease inhibitor that neutralizes neutrophil elastase and proteinase 3 via a reactive-center loop centered on Met358; the Z-allele mutation (Glu342Lys) disrupts a stabilizing salt bridge, causing misfolding and intracellular polymerization in the ER of hepatocytes (cleared via autophagy/TFEB-dependent autolysosomes), while circulating A1AT is actively transcytosed across pulmonary endothelium via SR-BI/clathrin-mediated endocytosis, inhibits caspase-3/8 and ADAM17/TACE independently of its elastase-inhibitory activity, suppresses NF-κB and iNOS-dependent NO production in macrophages, promotes chondrocyte differentiation via PKA/CREB and Wnt/β-catenin pathways, regulates preadipocyte proliferation and UCP1 expression through an EphB2 receptor complex, inhibits osteoclastogenesis by suppressing RANK/DC-STAMP signaling, and is itself translationally regulated by NQO1 (which binds its 3'UTR) and by miR-320c, with its 5'-UTR forming a defined multi-helix structure that optimizes translation; in MASH, hepatic IL-1β inhibits A1AT transcription through HNF4α, disinhibiting PR3-mediated cleavage of IL-32γ to drive liver inflammation and fibrosis."},"narrative":{"mechanistic_narrative":"SERPINA1 (A1AT) is a secreted serine protease inhibitor whose canonical function is the neutralization of neutrophil elastase through a reactive-center loop centered on Met358 displayed on an external stressed loop, with two salt bridges (Glu342-Lys290; Glu263-Lys387) stabilizing the native fold [PMID:3289385]. Disruption of these stabilizing interactions by natural missense variants causes intracellular polymerization and secretion failure: numerous variants form ER polymers and fail to secrete, while the Z (Glu342Lys) substitution drives polymer assembly that can incorporate wild-type M subunits into heteropolymers in vivo [PMID:29232161, PMID:32699193]. This toxic hepatocyte polymer burden is cleared through autophagy/lysosomal degradation, and forced TFEB expression promotes autolysosomal polymer clearance while lowering monomer expression [PMID:23584152]. Beyond protease inhibition, A1AT exerts elastase-inhibitory-independent activities: native and oxidized forms equally inhibit caspase-3/caspase-8 and reduce ADAM17/TACE activity to limit hepatocyte apoptosis [PMID:24449466], and it suppresses macrophage iNOS expression and NF-κB activation to dampen NO production [PMID:22975343]. A1AT also acts as a hepatocyte-derived signaling ligand, complexing with the EphB2 receptor to drive preadipocyte proliferation, adipose browning, and UCP1-dependent thermogenesis [PMID:39532838], inhibiting RANKL-induced osteoclastogenesis by suppressing RANK and DC-STAMP [PMID:28332697], and promoting chondrogenic differentiation through PKA/CREB and Wnt/β-catenin signaling [PMID:33788977]. Circulating A1AT reaches the lung epithelium by active transcytosis across pulmonary endothelium, with SR-BI serving as a key endocytic receptor via clathrin- and caveolae-mediated uptake [PMID:24743137, PMID:26092999]. Its expression is tuned at multiple levels, including NQO1 binding to the SERPINA1 3'UTR to promote translation [PMID:27515817], a defined multi-helix 5'-UTR structure that optimizes translation initiation [PMID:36107773], and transcriptional repression by IL-1β via HNF4α in metabolic liver disease, where loss of A1AT disinhibits proteinase-3-mediated cleavage of IL-32γ to drive inflammation and fibrosis [PMID:39939782].","teleology":[{"year":1988,"claim":"Established the molecular basis of protease inhibition and protein stability, defining the active-site residue and the salt bridges whose disruption causes disease variants.","evidence":"Structural and biochemical characterization of natural protein variants","pmids":["3289385"],"confidence":"High","gaps":["Does not address non-canonical (elastase-independent) functions","Mechanism of polymer assembly not resolved at this stage"]},{"year":1987,"claim":"Determined that A1AT is N-glycosylated on three asparagines during secretion, clarifying post-translational processing in the secretory pathway.","evidence":"Recombinant expression in yeast with endoglycosidase H treatment","pmids":["3315863"],"confidence":"Medium","gaps":["Yeast glycosylation differs from human; in vivo human glycan structure not defined here","Functional consequence of glycosylation not tested"]},{"year":1993,"claim":"Extended A1AT expression beyond hepatocytes to intestinal enterocytes and Paneth cells, indicating local production at mucosal surfaces.","evidence":"In situ hybridization and double-label immunohistochemistry of human gut","pmids":["8408656"],"confidence":"High","gaps":["Functional role of intestinal A1AT not established","Relative contribution to systemic A1AT pool unknown"]},{"year":2002,"claim":"Identified mammary gland expression and milk A1AT, with a protease-protective role suggesting a function in protecting milk proteins during digestion.","evidence":"RT-PCR, milk ELISA, in vitro pepsin/pancreatin digestion assays","pmids":["12324297"],"confidence":"Medium","gaps":["In vivo relevance to infant nutrition not demonstrated","Single lab"]},{"year":2012,"claim":"Revealed an elastase-independent anti-inflammatory mechanism whereby A1AT suppresses macrophage NO production through iNOS and NF-κB inhibition.","evidence":"Macrophage stimulation assays plus exhaled NO in AAT-deficient subjects","pmids":["22975343"],"confidence":"Medium","gaps":["Direct molecular target upstream of NF-κB not identified","Receptor mediating macrophage uptake not defined here"]},{"year":2013,"claim":"Showed that boosting autophagy/lysosomal biogenesis via TFEB clears toxic Z polymer, defining a degradation route for misfolded intracellular A1AT.","evidence":"Liver-directed TFEB gene transfer in a SERPINA1 deficiency mouse model","pmids":["23584152"],"confidence":"Medium","gaps":["Selectivity of polymer vs monomer clearance not fully dissected","Long-term efficacy and safety not established"]},{"year":2014,"claim":"Demonstrated that A1AT inhibits caspase-3/8 and ADAM17 independently of elastase inhibition, establishing a cytoprotective antiapoptotic role.","evidence":"Cell-free caspase assays and mouse acute liver failure models with native vs oxidized A1AT","pmids":["24449466"],"confidence":"High","gaps":["Mode of caspase inhibition (direct vs indirect) not structurally resolved","Intracellular access of extracellular A1AT to caspases not fully explained"]},{"year":2014,"claim":"Established that A1AT is actively transcytosed across pulmonary endothelium, explaining how circulating A1AT reaches lung epithelium.","evidence":"Confocal time-lapse, transwell co-culture, and intravital microscopy with tunicamycin","pmids":["24743137"],"confidence":"Medium","gaps":["Receptor not yet identified at this stage","Quantitative contribution to alveolar A1AT unknown"]},{"year":2015,"claim":"Identified SR-BI as a key endocytic receptor mediating A1AT uptake by pulmonary endothelium via clathrin- and caveolae-dependent routes.","evidence":"EM of gold-labeled A1AT, SR-BI Co-IP, siRNA, neutralizing antibody, Scarb1 KO mice","pmids":["26092999"],"confidence":"High","gaps":["Residual 50-70% uptake implies additional receptors","Single lab"]},{"year":2016,"claim":"Uncovered translational control of A1AT by NQO1 binding the SERPINA1 3'UTR, linking redox status to A1AT protein output.","evidence":"RIP-microarray, biotin pulldown, polysome profiling, luciferase reporter, NQO1-KO mice","pmids":["27515817"],"confidence":"High","gaps":["Precise NQO1 binding element not mapped","Mechanistic coupling to ribosome loading not structurally defined"]},{"year":2017,"claim":"Characterized A1AT as an inhibitor of RANKL-driven osteoclastogenesis through suppression of RANK and DC-STAMP, expanding its role to bone remodeling.","evidence":"In vitro osteoclast differentiation, receptor and gene expression, resorption assays","pmids":["28332697"],"confidence":"Medium","gaps":["Receptor mediating A1AT effect on osteoclast precursors unknown","No in vivo bone phenotype shown"]},{"year":2017,"claim":"Identified a negative feedback loop in which exogenous A1AT lowers its own SERPINA1 mRNA in hepatocytes and PBMCs.","evidence":"Dose-response treatment of primary human hepatocytes and PBMCs with qRT-PCR","pmids":["28486562"],"confidence":"Medium","gaps":["Signaling pathway mediating autoregulation not defined","Relevance to augmentation therapy dosing unclear"]},{"year":2017,"claim":"Showed that carbamylated A1AT is an autoantigen recognized by anti-CarP antibodies in rheumatoid arthritis, linking A1AT modification to autoimmunity.","evidence":"Ion exchange fractionation, mass spectrometry, ELISA, synovial fluid detection","pmids":["28291659"],"confidence":"Medium","gaps":["Pathogenic role of anti-Ca-A1AT antibodies not established","Carbamylation site stoichiometry in vivo unknown"]},{"year":2018,"claim":"Functionally classified novel missense variants by polymerization and secretion behavior, refining genotype-to-pathology relationships.","evidence":"HEK293T overexpression with PAS staining, pulse-chase, elastase assays","pmids":["29232161"],"confidence":"Medium","gaps":["Overexpression system may not reflect endogenous folding kinetics","Clinical penetrance of variants not addressed"]},{"year":2020,"claim":"Provided direct structural evidence that wild-type M A1AT is incorporated into Z polymers in vivo, demonstrating heteropolymerization.","evidence":"Antibody epitope crystallography and negative-stain EM of Fab-labeled liver-explant polymers","pmids":["32699193"],"confidence":"High","gaps":["Full polymer interface structure not solved","Functional consequence of M incorporation for MZ carriers not quantified"]},{"year":2020,"claim":"Defined how A1AT deficiency dysregulates neutrophil degranulation via Rac2/PAR2/ROS, and showed augmentation therapy normalizes the membrane proteome.","evidence":"Neutrophil membrane proteomics, FRET, ELISA, in vivo augmentation cohort","pmids":["32060059"],"confidence":"Medium","gaps":["Direct A1AT target in the Rac2/PAR2 axis not identified","Single lab"]},{"year":2021,"claim":"Established A1AT as a promoter of chondrogenic differentiation acting through PKA/CREB activation and Wnt/β-catenin inhibition.","evidence":"SERPINA1 transfection and recombinant protein in human chondrocytes with pathway and gene analysis plus arthritis models","pmids":["33788977"],"confidence":"Medium","gaps":["Receptor transducing the chondrocyte signal unknown","Direct vs indirect pathway engagement unresolved"]},{"year":2021,"claim":"Linked SERPINA1 to placental biology and preterm birth through cytoskeletal/Slit-Robo/ECM pathway regulation in trophoblasts and human genetic data.","evidence":"siRNA knockdown with pathway analysis, whole exome sequencing, placental proteomics","pmids":["35477570"],"confidence":"Medium","gaps":["Mechanism connecting A1AT to actin/Slit-Robo regulation unclear","Causality of rare variants not functionally proven"]},{"year":2024,"claim":"Identified A1AT as a hepatocyte-derived EphB2 ligand controlling adipose browning and systemic metabolism, a receptor-mediated signaling role.","evidence":"Liver-specific transgenic and KO mice, EphB2 Co-IP, adipocyte assays, metabolic phenotyping","pmids":["39532838"],"confidence":"High","gaps":["Structural basis of A1AT-EphB2 interaction not solved","Whether protease-inhibitory activity is required not determined"]},{"year":2025,"claim":"Positioned A1AT in a MASH circuit where IL-1β/HNF4α represses A1AT, disinhibiting PR3 cleavage of IL-32γ to drive liver inflammation and fibrosis.","evidence":"Quintuple Serpina1 KO mice, cleavage-resistant IL-32γ mutant, HNF4α analysis, in vivo A1AT restoration","pmids":["39939782"],"confidence":"High","gaps":["Direct HNF4α binding at the SERPINA1 promoter not structurally mapped","Translation of PR3 inhibition to human MASH not established"]},{"year":null,"claim":"How A1AT's diverse receptor-mediated and protease-independent signaling functions are integrated, and which require versus do not require its protease-inhibitory activity, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model linking elastase inhibition, EphB2 binding, and caspase inhibition","Receptors for several non-canonical effects (chondrocyte, osteoclast) unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,6]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,6,14]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[17]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,4]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[7,11]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,16]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[4,5]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,10,11,18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[17,15]}],"complexes":[],"partners":["EPHB2","SCARB1","NQO1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P01009","full_name":"Alpha-1-antitrypsin","aliases":["Alpha-1 protease inhibitor","Alpha-1-antiproteinase","Serpin A1"],"length_aa":418,"mass_kda":46.7,"function":"Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin Reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE)","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/P01009/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SERPINA1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SERPINA1","total_profiled":1310},"omim":[{"mim_id":"620965","title":"SMALL VCP-INTERACTING PROTEIN; SVIP","url":"https://www.omim.org/entry/620965"},{"mim_id":"617471","title":"SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 12; SERPINA12","url":"https://www.omim.org/entry/617471"},{"mim_id":"616942","title":"PROTEIN DISULFIDE ISOMERASE, FAMILY A, MEMBER 5; PDIA5","url":"https://www.omim.org/entry/616942"},{"mim_id":"613490","title":"ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD","url":"https://www.omim.org/entry/613490"},{"mim_id":"609443","title":"CHYMOTRYPSIN-LIKE ELASTASE FAMILY, MEMBER 2A; CELA2A","url":"https://www.omim.org/entry/609443"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Vesicles","reliability":"Enhanced"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":31416.7}],"url":"https://www.proteinatlas.org/search/SERPINA1"},"hgnc":{"alias_symbol":["AAT","A1A","PI1","alpha-1-antitrypsin","A1AT","alpha1AT"],"prev_symbol":["PI"]},"alphafold":{"accession":"P01009","domains":[{"cath_id":"3.30.497.10","chopping":"46-215_316-362","consensus_level":"medium","plddt":95.139,"start":46,"end":362},{"cath_id":"2.30.39.10","chopping":"220-312_389-411","consensus_level":"medium","plddt":96.2537,"start":220,"end":411}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01009","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01009-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01009-F1-predicted_aligned_error_v6.png","plddt_mean":88.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SERPINA1","jax_strain_url":"https://www.jax.org/strain/search?query=SERPINA1"},"sequence":{"accession":"P01009","fasta_url":"https://rest.uniprot.org/uniprotkb/P01009.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01009/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01009"}},"corpus_meta":[{"pmid":"3289385","id":"PMC_3289385","title":"Molecular basis of alpha-1-antitrypsin deficiency.","date":"1988","source":"The American journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/3289385","citation_count":429,"is_preprint":false},{"pmid":"9447774","id":"PMC_9447774","title":"Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting.","date":"1997","source":"Bulletin of the World Health Organization","url":"https://pubmed.ncbi.nlm.nih.gov/9447774","citation_count":170,"is_preprint":false},{"pmid":"2696185","id":"PMC_2696185","title":"The alpha 1-antitrypsin gene and its deficiency states.","date":"1989","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/2696185","citation_count":148,"is_preprint":false},{"pmid":"22634722","id":"PMC_22634722","title":"Expanding the clinical indications for α(1)-antitrypsin therapy.","date":"2012","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/22634722","citation_count":128,"is_preprint":false},{"pmid":"8408656","id":"PMC_8408656","title":"Cell-specific expression of alpha 1-antitrypsin in human intestinal epithelium.","date":"1993","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/8408656","citation_count":113,"is_preprint":false},{"pmid":"19409369","id":"PMC_19409369","title":"Protein-cofactor interactions in bioenergetic complexes: the role of the A1A and A1B phylloquinones in Photosystem I.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19409369","citation_count":103,"is_preprint":false},{"pmid":"24854541","id":"PMC_24854541","title":"Immune-modulating effects of alpha-1 antitrypsin.","date":"2014","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24854541","citation_count":93,"is_preprint":false},{"pmid":"35748699","id":"PMC_35748699","title":"Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.","date":"2022","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35748699","citation_count":89,"is_preprint":false},{"pmid":"33790624","id":"PMC_33790624","title":"Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum.","date":"2021","source":"The application of clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33790624","citation_count":84,"is_preprint":false},{"pmid":"18353624","id":"PMC_18353624","title":"Alpha-1 antitrypsin Null mutations and severity of emphysema.","date":"2008","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18353624","citation_count":79,"is_preprint":false},{"pmid":"18515255","id":"PMC_18515255","title":"SERPINA1 gene variants in individuals from the general population with reduced alpha1-antitrypsin concentrations.","date":"2008","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18515255","citation_count":64,"is_preprint":false},{"pmid":"34848258","id":"PMC_34848258","title":"Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.","date":"2021","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34848258","citation_count":63,"is_preprint":false},{"pmid":"2679136","id":"PMC_2679136","title":"The alpha 1-antitrypsin gene and emphysema.","date":"1989","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/2679136","citation_count":60,"is_preprint":false},{"pmid":"33632708","id":"PMC_33632708","title":"Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.","date":"2021","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/33632708","citation_count":59,"is_preprint":false},{"pmid":"12324297","id":"PMC_12324297","title":"Alpha(1)-antitrypsin and antichymotrypsin in human milk: origin, concentrations, and stability.","date":"2002","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/12324297","citation_count":59,"is_preprint":false},{"pmid":"32051168","id":"PMC_32051168","title":"α1-Antitrypsin deficiency and chronic respiratory disorders.","date":"2020","source":"European respiratory review : an official journal of the European Respiratory Society","url":"https://pubmed.ncbi.nlm.nih.gov/32051168","citation_count":58,"is_preprint":false},{"pmid":"31487965","id":"PMC_31487965","title":"Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31487965","citation_count":55,"is_preprint":false},{"pmid":"24449466","id":"PMC_24449466","title":"α-1-antitrypsin inhibits acute liver failure in mice.","date":"2014","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/24449466","citation_count":54,"is_preprint":false},{"pmid":"25425243","id":"PMC_25425243","title":"Identification and characterisation of eight novel SERPINA1 Null mutations.","date":"2014","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25425243","citation_count":54,"is_preprint":false},{"pmid":"3315863","id":"PMC_3315863","title":"Glycosylation and secretion of human alpha-1-antitrypsin by yeast.","date":"1987","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/3315863","citation_count":54,"is_preprint":false},{"pmid":"27296815","id":"PMC_27296815","title":"Alpha-1-antitrypsin (SERPINA1) mutation spectrum: Three novel variants and haplotype characterization of rare deficiency alleles identified in Portugal.","date":"2016","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27296815","citation_count":52,"is_preprint":false},{"pmid":"32379724","id":"PMC_32379724","title":"Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32379724","citation_count":49,"is_preprint":false},{"pmid":"16088434","id":"PMC_16088434","title":"A review of alpha-1 antitrypsin deficiency.","date":"2005","source":"Seminars in respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16088434","citation_count":49,"is_preprint":false},{"pmid":"25224412","id":"PMC_25224412","title":"α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25224412","citation_count":46,"is_preprint":false},{"pmid":"23584152","id":"PMC_23584152","title":"Autophagy master regulator TFEB induces clearance of toxic SERPINA1/α-1-antitrypsin polymers.","date":"2013","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/23584152","citation_count":46,"is_preprint":false},{"pmid":"6763344","id":"PMC_6763344","title":"Alpha-1-antitrypsin: an ignored protein in understanding liver disease.","date":"1982","source":"Seminars in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/6763344","citation_count":45,"is_preprint":false},{"pmid":"12571637","id":"PMC_12571637","title":"Gene therapy progress and prospects: alpha-1 antitrypsin.","date":"2003","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12571637","citation_count":44,"is_preprint":false},{"pmid":"9279535","id":"PMC_9279535","title":"alpha 1-Antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis: genetic and clinical implications.","date":"1997","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9279535","citation_count":43,"is_preprint":false},{"pmid":"30009048","id":"PMC_30009048","title":"SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency.","date":"2018","source":"Journal of nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/30009048","citation_count":43,"is_preprint":false},{"pmid":"24743137","id":"PMC_24743137","title":"Active trafficking of alpha 1 antitrypsin across the lung endothelium.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24743137","citation_count":42,"is_preprint":false},{"pmid":"1439881","id":"PMC_1439881","title":"Molecular biology and genetics of alpha 1-antitrypsin deficiency.","date":"1992","source":"Seminars in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/1439881","citation_count":41,"is_preprint":false},{"pmid":"28291659","id":"PMC_28291659","title":"Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis.","date":"2017","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/28291659","citation_count":40,"is_preprint":false},{"pmid":"34408833","id":"PMC_34408833","title":"Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency.","date":"2021","source":"Therapeutic advances in chronic disease","url":"https://pubmed.ncbi.nlm.nih.gov/34408833","citation_count":38,"is_preprint":false},{"pmid":"15389208","id":"PMC_15389208","title":"Alpha-1-antitrypsin associated panniculitis: the MS variant.","date":"2004","source":"Journal of the American Academy of Dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15389208","citation_count":38,"is_preprint":false},{"pmid":"30761929","id":"PMC_30761929","title":"Emphysema: looking beyond alpha-1 antitrypsin deficiency.","date":"2019","source":"Expert review of respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30761929","citation_count":37,"is_preprint":false},{"pmid":"23527792","id":"PMC_23527792","title":"Gene-based therapy for alpha-1 antitrypsin deficiency.","date":"2013","source":"COPD","url":"https://pubmed.ncbi.nlm.nih.gov/23527792","citation_count":37,"is_preprint":false},{"pmid":"20955965","id":"PMC_20955965","title":"Alpha-1-antitrypsin deficiency.","date":"2010","source":"Best practice & research. Clinical gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/20955965","citation_count":36,"is_preprint":false},{"pmid":"25066184","id":"PMC_25066184","title":"Alpha-1 antitrypsin and liver disease: mechanisms of injury and novel interventions.","date":"2014","source":"Expert review of gastroenterology & hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/25066184","citation_count":36,"is_preprint":false},{"pmid":"14694355","id":"PMC_14694355","title":"Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies.","date":"2004","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/14694355","citation_count":35,"is_preprint":false},{"pmid":"27564673","id":"PMC_27564673","title":"Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease.","date":"2016","source":"Annals of the American Thoracic Society","url":"https://pubmed.ncbi.nlm.nih.gov/27564673","citation_count":34,"is_preprint":false},{"pmid":"26141700","id":"PMC_26141700","title":"Alternative transcripts of the SERPINA1 gene in alpha-1 antitrypsin deficiency.","date":"2015","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26141700","citation_count":34,"is_preprint":false},{"pmid":"33788977","id":"PMC_33788977","title":"Alpha-1-antitrypsin reduces inflammation and exerts chondroprotection in arthritis.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33788977","citation_count":32,"is_preprint":false},{"pmid":"30723786","id":"PMC_30723786","title":"Alpha-1 Antitrypsin Therapy for Autoimmune Disorders.","date":"2018","source":"Chronic obstructive pulmonary diseases (Miami, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/30723786","citation_count":32,"is_preprint":false},{"pmid":"27115949","id":"PMC_27115949","title":"Alpha-1 Antitrypsin and Lung Cell Apoptosis.","date":"2016","source":"Annals of the American Thoracic Society","url":"https://pubmed.ncbi.nlm.nih.gov/27115949","citation_count":31,"is_preprint":false},{"pmid":"17562108","id":"PMC_17562108","title":"Alpha-1-antitrypsin deficiency: current concepts.","date":"2007","source":"Lung","url":"https://pubmed.ncbi.nlm.nih.gov/17562108","citation_count":30,"is_preprint":false},{"pmid":"21498872","id":"PMC_21498872","title":"Gene therapy for alpha-1 antitrypsin deficiency.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21498872","citation_count":30,"is_preprint":false},{"pmid":"1749216","id":"PMC_1749216","title":"Alpha 1-antitrypsin deficiency and liver disease.","date":"1991","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/1749216","citation_count":30,"is_preprint":false},{"pmid":"22500781","id":"PMC_22500781","title":"A review of augmentation therapy for alpha-1 antitrypsin deficiency.","date":"2012","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22500781","citation_count":30,"is_preprint":false},{"pmid":"29232161","id":"PMC_29232161","title":"Characterization of Novel Missense Variants of SERPINA1 Gene Causing Alpha-1 Antitrypsin Deficiency.","date":"2018","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29232161","citation_count":29,"is_preprint":false},{"pmid":"16510030","id":"PMC_16510030","title":"Alpha-1-antitrypsin deficiency: diagnosis, pathophysiology, and management.","date":"2006","source":"Current gastroenterology reports","url":"https://pubmed.ncbi.nlm.nih.gov/16510030","citation_count":28,"is_preprint":false},{"pmid":"24011266","id":"PMC_24011266","title":"Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection.","date":"2013","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/24011266","citation_count":28,"is_preprint":false},{"pmid":"27515817","id":"PMC_27515817","title":"Novel RNA-binding activity of NQO1 promotes SERPINA1 mRNA translation.","date":"2016","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27515817","citation_count":28,"is_preprint":false},{"pmid":"22975343","id":"PMC_22975343","title":"Alpha-1-antitrypsin inhibits nitric oxide production.","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22975343","citation_count":27,"is_preprint":false},{"pmid":"19484794","id":"PMC_19484794","title":"Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression.","date":"2009","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19484794","citation_count":26,"is_preprint":false},{"pmid":"33824927","id":"PMC_33824927","title":"Alpha-1 antitrypsin deficiency liver disease.","date":"2021","source":"Translational gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33824927","citation_count":24,"is_preprint":false},{"pmid":"29607607","id":"PMC_29607607","title":"Alpha-1-antitrypsin in cell and organ transplantation.","date":"2018","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/29607607","citation_count":23,"is_preprint":false},{"pmid":"25723058","id":"PMC_25723058","title":"Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?","date":"2014","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/25723058","citation_count":23,"is_preprint":false},{"pmid":"32668173","id":"PMC_32668173","title":"Advances in Alpha-1 Antitrypsin Gene Therapy.","date":"2020","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32668173","citation_count":22,"is_preprint":false},{"pmid":"6607204","id":"PMC_6607204","title":"alpha-1-Antitrypsin deficiency.","date":"1984","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/6607204","citation_count":22,"is_preprint":false},{"pmid":"32699193","id":"PMC_32699193","title":"Intrahepatic heteropolymerization of M and Z alpha-1-antitrypsin.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32699193","citation_count":22,"is_preprint":false},{"pmid":"35477570","id":"PMC_35477570","title":"Human placental proteomics and exon variant studies link AAT/SERPINA1 with spontaneous preterm birth.","date":"2022","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35477570","citation_count":22,"is_preprint":false},{"pmid":"27115946","id":"PMC_27115946","title":"Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency.","date":"2016","source":"Annals of the American Thoracic Society","url":"https://pubmed.ncbi.nlm.nih.gov/27115946","citation_count":22,"is_preprint":false},{"pmid":"28364818","id":"PMC_28364818","title":"Liver Transplantation in Alpha-1 Antitrypsin Deficiency.","date":"2017","source":"Clinics in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/28364818","citation_count":21,"is_preprint":false},{"pmid":"21426261","id":"PMC_21426261","title":"α(1)-antitrypsin deficiency and inflammation.","date":"2011","source":"Expert review of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21426261","citation_count":20,"is_preprint":false},{"pmid":"36107773","id":"PMC_36107773","title":"Global 5'-UTR RNA structure regulates translation of a SERPINA1 mRNA.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/36107773","citation_count":20,"is_preprint":false},{"pmid":"32060059","id":"PMC_32060059","title":"α1 Antitrypsin therapy modulates the neutrophil membrane proteome and secretome.","date":"2020","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/32060059","citation_count":20,"is_preprint":false},{"pmid":"28332697","id":"PMC_28332697","title":"Alpha-1 antitrypsin inhibits RANKL-induced osteoclast formation and functions.","date":"2017","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/28332697","citation_count":20,"is_preprint":false},{"pmid":"11232197","id":"PMC_11232197","title":"Liver injury in alpha 1-antitrypsin deficiency.","date":"2000","source":"Clinics in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/11232197","citation_count":19,"is_preprint":false},{"pmid":"26321041","id":"PMC_26321041","title":"SERPINA1 Full-Gene Sequencing Identifies Rare Mutations Not Detected in Targeted Mutation Analysis.","date":"2015","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/26321041","citation_count":19,"is_preprint":false},{"pmid":"1447962","id":"PMC_1447962","title":"Genetic variants of alpha-1-antitrypsin (AAT).","date":"1992","source":"Liver","url":"https://pubmed.ncbi.nlm.nih.gov/1447962","citation_count":18,"is_preprint":false},{"pmid":"31957347","id":"PMC_31957347","title":"CSF SerpinA1 in Creutzfeldt-Jakob disease and frontotemporal lobar degeneration.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31957347","citation_count":18,"is_preprint":false},{"pmid":"26092999","id":"PMC_26092999","title":"Scavenger receptor class B, type I-mediated uptake of A1AT by pulmonary endothelial cells.","date":"2015","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26092999","citation_count":18,"is_preprint":false},{"pmid":"37993348","id":"PMC_37993348","title":"Alpha-1 antitrypsin deficiency.","date":"2023","source":"Medicina clinica","url":"https://pubmed.ncbi.nlm.nih.gov/37993348","citation_count":17,"is_preprint":false},{"pmid":"28752442","id":"PMC_28752442","title":"Pathophysiology of Alpha-1 Antitrypsin Lung Disease.","date":"2017","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/28752442","citation_count":17,"is_preprint":false},{"pmid":"30131830","id":"PMC_30131830","title":"Update on α1-antitrypsin deficiency.","date":"2018","source":"Breathe (Sheffield, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30131830","citation_count":17,"is_preprint":false},{"pmid":"36825473","id":"PMC_36825473","title":"Gene therapy for alpha-1 antitrypsin deficiency: an update.","date":"2023","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36825473","citation_count":16,"is_preprint":false},{"pmid":"25442121","id":"PMC_25442121","title":"Molecular pathogenesis of alpha-1-antitrypsin deficiency.","date":"2014","source":"Revue des maladies respiratoires","url":"https://pubmed.ncbi.nlm.nih.gov/25442121","citation_count":16,"is_preprint":false},{"pmid":"35698951","id":"PMC_35698951","title":"miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease.","date":"2021","source":"Archivos de bronconeumologia","url":"https://pubmed.ncbi.nlm.nih.gov/35698951","citation_count":16,"is_preprint":false},{"pmid":"37236906","id":"PMC_37236906","title":"Alpha-1 antitrypsin deficiency and Pi*S and Pi*Z SERPINA1 variants are associated with asthma exacerbations.","date":"2024","source":"Pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/37236906","citation_count":15,"is_preprint":false},{"pmid":"11744816","id":"PMC_11744816","title":"Alpha-1-antitrypsin deficiency and nephropathy.","date":"2002","source":"Nephron","url":"https://pubmed.ncbi.nlm.nih.gov/11744816","citation_count":15,"is_preprint":false},{"pmid":"28486562","id":"PMC_28486562","title":"Exogenous alpha 1-antitrypsin down-regulates SERPINA1 expression.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28486562","citation_count":15,"is_preprint":false},{"pmid":"1899256","id":"PMC_1899256","title":"Alpha 1-antitrypsin deficiency: pathogenesis and treatment.","date":"1991","source":"Hospital practice (Office ed.)","url":"https://pubmed.ncbi.nlm.nih.gov/1899256","citation_count":15,"is_preprint":false},{"pmid":"16997740","id":"PMC_16997740","title":"What we owe to alpha(1)-antitrypsin and to Carl-Bertil Laurell.","date":"2004","source":"COPD","url":"https://pubmed.ncbi.nlm.nih.gov/16997740","citation_count":15,"is_preprint":false},{"pmid":"18695797","id":"PMC_18695797","title":"[Alpha-1 antitrypsin deficiency: diagnosis and treatment].","date":"2008","source":"Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia","url":"https://pubmed.ncbi.nlm.nih.gov/18695797","citation_count":15,"is_preprint":false},{"pmid":"10904927","id":"PMC_10904927","title":"Alpha-1-antitrypsin deficiency, the serpinopathies and conformational disease.","date":"2000","source":"Journal of the Royal College of Physicians of London","url":"https://pubmed.ncbi.nlm.nih.gov/10904927","citation_count":15,"is_preprint":false},{"pmid":"31517326","id":"PMC_31517326","title":"SERPINA1 and HSD17B13 Gene Variants in Patients with Liver Fibrosis and Cirrhosis.","date":"2019","source":"Journal of gastrointestinal and liver diseases : JGLD","url":"https://pubmed.ncbi.nlm.nih.gov/31517326","citation_count":15,"is_preprint":false},{"pmid":"39401571","id":"PMC_39401571","title":"Editing Approaches to Treat Alpha-1 Antitrypsin Deficiency.","date":"2024","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/39401571","citation_count":14,"is_preprint":false},{"pmid":"2117160","id":"PMC_2117160","title":"Discovery of alpha 1-antitrypsin deficiency.","date":"1990","source":"Lung","url":"https://pubmed.ncbi.nlm.nih.gov/2117160","citation_count":14,"is_preprint":false},{"pmid":"1859394","id":"PMC_1859394","title":"The molecular genetics of alpha 1 antitrypsin deficiency.","date":"1991","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/1859394","citation_count":14,"is_preprint":false},{"pmid":"39532838","id":"PMC_39532838","title":"Hepatic SerpinA1 improves energy and glucose metabolism through regulation of preadipocyte proliferation and UCP1 expression.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39532838","citation_count":13,"is_preprint":false},{"pmid":"35868681","id":"PMC_35868681","title":"Alpha-1 Antitrypsin Deficiency Liver Disease.","date":"2022","source":"Clinics in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/35868681","citation_count":13,"is_preprint":false},{"pmid":"8396299","id":"PMC_8396299","title":"Alpha 1-antitrypsin deficiency: an overview.","date":"1993","source":"Acta clinica Belgica","url":"https://pubmed.ncbi.nlm.nih.gov/8396299","citation_count":13,"is_preprint":false},{"pmid":"11249642","id":"PMC_11249642","title":"Technology evaluation: transgenic alpha-1-antitrypsin (AAT), PPL therapeutics.","date":"2000","source":"Current opinion in molecular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/11249642","citation_count":13,"is_preprint":false},{"pmid":"36367950","id":"PMC_36367950","title":"Novel SERPINA1 Alleles Identified through a Large Alpha-1 Antitrypsin Deficiency Screening Program and Review of Known Variants.","date":"2023","source":"Chronic obstructive pulmonary diseases (Miami, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/36367950","citation_count":13,"is_preprint":false},{"pmid":"37093347","id":"PMC_37093347","title":"Plasma exosomal protein PLG and SERPINA1 in colorectal cancer diagnosis and coagulation abnormalities.","date":"2023","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37093347","citation_count":13,"is_preprint":false},{"pmid":"29163550","id":"PMC_29163550","title":"Evaluation of Alpha-1 Antitrypsin Levels and SERPINA1 Gene Polymorphisms in Sickle Cell Disease.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29163550","citation_count":13,"is_preprint":false},{"pmid":"35592360","id":"PMC_35592360","title":"Liver-directed SERPINA1 gene therapy attenuates progression of spontaneous and tobacco smoke-induced emphysema in α1-antitrypsin null mice.","date":"2022","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/35592360","citation_count":13,"is_preprint":false},{"pmid":"36805759","id":"PMC_36805759","title":"Soybean transporter AAT Rhg1 abundance increases along the nematode migration path and impacts vesiculation and ROS.","date":"2023","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36805759","citation_count":13,"is_preprint":false},{"pmid":"39939782","id":"PMC_39939782","title":"A1AT dysregulation of metabolically stressed hepatocytes by Kupffer cells drives MASH and fibrosis.","date":"2025","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39939782","citation_count":12,"is_preprint":false},{"pmid":"7988061","id":"PMC_7988061","title":"Alpha-1-antitrypsin deficiency and liver disease.","date":"1994","source":"Digestive diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/7988061","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45070,"output_tokens":5684,"usd":0.110235,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14389,"output_tokens":5537,"usd":0.105185,"stage2_stop_reason":"end_turn"},"total_usd":0.21542,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"SERPINA1/A1AT inhibits neutrophil elastase through an active site centered around Met358 contained within an external stressed loop on the surface of the molecule. Two salt bridges (Glu342-Lys290; Glu263-Lys387) are critical for protein stability; disruption of either causes distinct molecular pathology resulting in reduced serum A1AT levels.\",\n      \"method\": \"Molecular characterization of protein variants, structural analysis, active-site mutagenesis inference from natural variants\",\n      \"journal\": \"The American journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — active-site residue identified by structural and biochemical characterization, replicated across multiple variant studies and widely confirmed\",\n      \"pmids\": [\"3289385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The SERPINA1 gene is expressed in human intestinal enterocytes (villous and crypt) in vivo, and also in Paneth cells where it co-localizes with lysozyme, as demonstrated by in situ hybridization and double-label immunohistochemistry of human jejunum and ileum.\",\n      \"method\": \"In situ hybridization, double-label immunohistochemistry\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal direct localization methods (in situ hybridization + immunohistochemistry) applied to human tissue in vivo\",\n      \"pmids\": [\"8408656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Human A1AT is glycosylated on three asparagine residues during secretion. When expressed in yeast, the protein receives core carbohydrate on two or three asparagine residues; the secreted yeast form additionally acquires outer mannose chains (yeast-type), all removable by endoglycosidase H treatment.\",\n      \"method\": \"Recombinant expression in Saccharomyces cerevisiae, endoglycosidase H treatment, analysis of mnn9 mutant\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct biochemical reconstitution in yeast with enzymatic deglycosylation, single study\",\n      \"pmids\": [\"3315863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Alpha-1-antitrypsin is produced by the mammary gland (mRNA detected by PCR) and is present in human milk at high concentrations early in lactation. A1AT resists in vitro proteolysis by pepsin and pancreatin and, when present, protects lactoferrin from pancreatin-mediated digestion.\",\n      \"method\": \"RT-PCR of mammary gland cDNA, ELISA measurement in milk samples, in vitro digestion assay with pepsin/pancreatin\",\n      \"journal\": \"The American journal of clinical nutrition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — expression confirmed by PCR plus functional in vitro digestion assay showing protease-protective effect, single lab\",\n      \"pmids\": [\"12324297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A1AT is actively transcytosed across pulmonary endothelial cells to lung epithelial cells. Uptake involves the classical secretory/Golgi pathway; inhibition of Golgi secretion with tunicamycin increased intracellular A1AT retention but promoted non-classical secretion via microparticles. Polymerized A1AT or cigarette smoke exposure decreased transcytosis.\",\n      \"method\": \"Confocal time-lapse microscopy, transwell co-culture assays, two-photon intravital microscopy in mice, tunicamycin inhibition\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods including in vivo intravital imaging and in vitro transcytosis assay, single lab\",\n      \"pmids\": [\"24743137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A1AT uptake by pulmonary endothelial cells is mediated primarily by clathrin-coated vesicles and caveolae, and scavenger receptor class B type I (SR-BI) serves as a key receptor for A1AT endocytosis. SR-BI knockdown, neutralizing antibodies, or ligand competition reduced A1AT uptake by 30–50%. SR-BI null mice showed decreased lung A1AT after systemic administration.\",\n      \"method\": \"Transmission electron microscopy of gold-labeled A1AT, SR-BI immunoprecipitation, SCARB1 siRNA knockdown, neutralizing antibodies, Scarb1 knockout mice\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — receptor identified by Co-IP and confirmed with multiple orthogonal approaches (KD, neutralizing antibody, KO mice, EM), single lab\",\n      \"pmids\": [\"26092999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A1AT inhibits active caspase-3 and caspase-8 directly in liver homogenates and in a cell-free system in vitro. Both native and oxidized (elastase-inhibitory-activity-deficient) forms of A1AT were equally effective, indicating that the antiapoptotic effect is independent of elastase inhibitory activity. AAT treatment also reduced ADAM17 (TACE) activity and TNF-α levels in vivo.\",\n      \"method\": \"Cell-free in vitro caspase activity assays, liver homogenate assays, mouse models of acute liver failure (Jo2, acetaminophen, α-amanitin), native vs. oxidized A1AT comparison\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro caspase inhibition assay plus multiple in vivo disease models with mechanistic readouts, single lab\",\n      \"pmids\": [\"24449466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TFEB (transcription factor EB), a master regulator of autophagy and lysosomal biogenesis, when delivered by liver-directed gene transfer, reduces toxic Z-SERPINA1 polymer accumulation in hepatocytes. The mechanism involves increased degradation of SERPINA1 polymer in autolysosomes and decreased SERPINA1 monomer expression.\",\n      \"method\": \"Liver-directed TFEB gene transfer in mouse model of SERPINA1 deficiency, histological and biochemical analysis of polymer levels, apoptosis and fibrosis markers\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic intervention with defined pathway (autophagy/lysosomal) and mechanistic readout in vivo, single lab\",\n      \"pmids\": [\"23584152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NQO1 (NAD(P)H:quinone oxidoreductase 1) binds SERPINA1 mRNA at its 3'UTR and coding region, and promotes translation of A1AT without affecting mRNA levels. NQO1 silencing decreased polysome loading on SERPINA1 mRNA and reduced A1AT protein levels. NQO1-KO mice had reduced hepatic and serum A1AT and increased neutrophil elastase activity.\",\n      \"method\": \"Ribonucleoprotein immunoprecipitation (RIP) + microarray, biotin pulldown assay, polysome profiling, luciferase reporter assay, NQO1 siRNA knockdown, NQO1-KO mice\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — RIP, biotin pulldown, polysome profiling, reporter assay, and KO mice all used in one study; multiple orthogonal methods confirm mRNA binding and translational regulation\",\n      \"pmids\": [\"27515817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The 5'-UTR of the NM_000295.4 SERPINA1 transcript folds into a well-defined multi-helix structural domain that optimizes translation by maintaining accessibility at the translation initiation site. Mutations that disrupted the anchor helix of this domain led to non-native structures that created a stable helix near the initiation site, thereby decreasing translation.\",\n      \"method\": \"SHAPE (Selective 2'-Hydroxyl Acylation analyzed by Primer Extension) RNA structure probing, systematic mutagenesis of the 5'-UTR, luciferase reporter translation assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — RNA structure determined by SHAPE probing and validated by systematic mutagenesis with functional translation readout, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36107773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Z A1AT can form heteropolymers with wild-type M A1AT in vivo. A monoclonal antibody (mAb2H2) was developed that preferentially binds M over Z A1AT; its epitope was localized by crystallography to a region perturbed by the Z (Glu342Lys) substitution. Negative-stain electron microscopy of Fab-labeled polymers from an MZ heterozygote liver explant revealed that M A1AT comprises approximately 6% of polymer subunits in vivo.\",\n      \"method\": \"Monoclonal antibody epitope mapping by crystallography, negative-stain electron microscopy of Fab-labeled polymers from human liver explant\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure of antibody epitope plus EM of labeled in vivo polymers; direct structural demonstration of heteropolymerization\",\n      \"pmids\": [\"32699193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Seven novel SERPINA1 missense variants were functionally characterized in HEK293T cells. Variants S+S14F, I50N, A58D, F227C, and T249A formed intracellular polymers and failed to secrete AAT protein. Variant K328E showed intracellular retention and reduced antielastase activity. Variant E151K secreted normally without polymer formation.\",\n      \"method\": \"Overexpression in HEK293T cells, PAS staining, Western blotting, pulse-chase assay, elastase inhibition assay\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro functional assays with multiple readouts (polymerization, secretion, enzymatic activity) across multiple variants, single lab\",\n      \"pmids\": [\"29232161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Carbamylated alpha-1-antitrypsin (Ca-A1AT) is an antigenic target of anti-carbamylated protein (anti-CarP) antibodies in rheumatoid arthritis patients. A1AT contains surface-accessible lysines that can be carbamylated, and carbamylated A1AT peptides were identified in synovial fluid of an RA patient by mass spectrometry.\",\n      \"method\": \"Ion exchange chromatography fractionation of carbamylated FCS, mass spectrometry identification, ELISA with Ca-A1AT, mass spectrometry of synovial fluid\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protein identified as autoantigen by MS and confirmed by ELISA, with in vivo detection in synovial fluid, single lab\",\n      \"pmids\": [\"28291659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"AAT inhibits NO production in macrophages by suppressing iNOS expression and NF-κB activation, independent of MAPK signaling. AAT reduced intracellular translocation of exogenous AAT in stimulated cells. In vivo, individuals with genetic AAT deficiency had significantly increased exhaled NO compared to healthy controls.\",\n      \"method\": \"RAW 264.7 cell stimulation assays, NO measurement, iNOS and NF-κB activation assays, MAPK phosphorylation assays, comparison with synthetic serine protease inhibitor CE-2072, exhaled NO measurement in AAT-deficient subjects\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanistic dissection with NF-κB and iNOS readouts plus in vivo human correlation, single lab\",\n      \"pmids\": [\"22975343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AAT dose-dependently inhibited RANKL-induced osteoclast formation from bone marrow macrophages and RAW264.7 cells. Mechanistically, AAT inhibited M-CSF-induced RANK surface expression on osteoclast precursors, suppressed RANKL-induced TNF-α production, and inhibited DC-STAMP gene expression and CD9 surface expression. AAT treatment significantly inhibited osteoclast-mediated mineral resorption.\",\n      \"method\": \"In vitro osteoclast differentiation assay, gene expression analysis, RANK surface expression assay, mineral resorption assay\",\n      \"journal\": \"Molecular medicine (Cambridge, Mass.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic readouts in vitro (receptor expression, gene expression, functional resorption), single lab\",\n      \"pmids\": [\"28332697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In human chondrocytes, SERPINA1 transfection and recombinant AAT protein promoted chondrogenic differentiation through activation of PKA-dependent CREB signaling and inhibition of Wnt/β-catenin pathways, upregulating col2a1, acan, and sox9 while downregulating mmp13 and adamts5.\",\n      \"method\": \"SERPINA1 transfection in human chondrocytes, signaling pathway analysis (PKA/CREB, Wnt/β-catenin), gene expression analysis, in vivo arthritis models (KBxN serum, neutrophil elastase)\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro pathway identification with two signaling readouts plus in vivo arthritis models, single lab\",\n      \"pmids\": [\"33788977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In AATD neutrophils, increased degranulation involves Rac2 activation leading to PAR2 activation by serine proteinases, resulting in enhanced reactive oxygen species production. AAT reduced primary granule release; augmentation therapy in vivo resolved the elevated surface abundance of neutrophil elastase and altered the AATD neutrophil membrane proteome toward that of non-AATD COPD.\",\n      \"method\": \"Label-free tandem mass spectrometry of neutrophil membrane proteome, Western blot, ELISA, FRET analysis, in vivo augmentation therapy cohort comparison\",\n      \"journal\": \"The European respiratory journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomics plus multiple orthogonal validation methods and in vivo human cohort; mechanistic pathway (Rac2→PAR2→ROS) identified, single lab\",\n      \"pmids\": [\"32060059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Hepatocyte-derived SerpinA1/A1AT forms a complex with EphB2 receptor and regulates its downstream signaling in adipocytes, promoting preadipocyte proliferation and increasing UCP1 expression to activate mitochondrial thermogenesis. Liver-specific SerpinA1 transgenic mice showed increased adipose browning, reduced adiposity, and improved glucose tolerance; SerpinA1 KO mice had impaired thermogenesis, obesity, and insulin resistance.\",\n      \"method\": \"Liver-specific transgenic overexpression, SerpinA1 knockout mice, co-immunoprecipitation (EphB2 complex), gene expression and protein assays in adipocytes, metabolic phenotyping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor binding identified by Co-IP, complementary gain- and loss-of-function mouse models with defined metabolic phenotypes, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39532838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In MASH, hepatic IL-1β produced by Kupffer cells transcriptionally inhibits A1AT expression via HNF4α. Loss of A1AT increases activity of proteinase 3 (PR3), which cleaves IL-32γ and converts it from an anti-inflammatory/antifibrogenic cytokine into a KC activator, thereby promoting MASH and fibrosis progression. A1AT restoration or PR3 inhibition mitigated MASH in vivo.\",\n      \"method\": \"Quintuple Serpina1a-e knockout mice on fast-food diet, IL-1β stimulation, PR3 activity assays, IL-32γ V104A cleavage-resistant mutant, cytokine arrays, in vivo A1AT restoration, transcription factor (HNF4α) analysis\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — KO mice, cleavage-resistant mutant, transcription factor identification, and in vivo rescue all used; multiple orthogonal methods establishing pathway position, single lab\",\n      \"pmids\": [\"39939782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"siRNA knockdown of SERPINA1 in trophoblast-derived HTR8/SVneo cells markedly affected actin cytoskeleton pathway regulation, Slit-Robo signaling, and extracellular matrix organization. Rare damaging SERPINA1 variants were identified in families with recurrent spontaneous preterm deliveries, and A1AT protein levels were downregulated in placental tissue from spontaneous preterm births.\",\n      \"method\": \"siRNA knockdown with pathway analysis, whole exome sequencing, placental proteomics and mRNA quantification, immunoelectron microscopy\",\n      \"journal\": \"BMC medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with defined pathway readouts plus human exome and proteomic data, single lab\",\n      \"pmids\": [\"35477570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Exogenous A1AT dose-dependently reduced SERPINA1 mRNA expression in primary human hepatocytes (including AAT-deficient patient hepatocytes), an effect potentiated by Oncostatin M. Exogenous A1AT also reduced SERPINA1 expression in human peripheral blood mononuclear cells, suggesting a negative feedback mechanism on its own expression.\",\n      \"method\": \"Treatment of primary human hepatocytes and PBMCs with purified A1AT, qRT-PCR for SERPINA1 mRNA, dose-response analysis, OSM co-stimulation, analysis of lung tissue from patients on augmentation therapy\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct treatment of primary human cells with dose-response and multiple cell types tested, single lab\",\n      \"pmids\": [\"28486562\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SERPINA1/A1AT is a 52-kDa hepatocyte-derived serine protease inhibitor that neutralizes neutrophil elastase and proteinase 3 via a reactive-center loop centered on Met358; the Z-allele mutation (Glu342Lys) disrupts a stabilizing salt bridge, causing misfolding and intracellular polymerization in the ER of hepatocytes (cleared via autophagy/TFEB-dependent autolysosomes), while circulating A1AT is actively transcytosed across pulmonary endothelium via SR-BI/clathrin-mediated endocytosis, inhibits caspase-3/8 and ADAM17/TACE independently of its elastase-inhibitory activity, suppresses NF-κB and iNOS-dependent NO production in macrophages, promotes chondrocyte differentiation via PKA/CREB and Wnt/β-catenin pathways, regulates preadipocyte proliferation and UCP1 expression through an EphB2 receptor complex, inhibits osteoclastogenesis by suppressing RANK/DC-STAMP signaling, and is itself translationally regulated by NQO1 (which binds its 3'UTR) and by miR-320c, with its 5'-UTR forming a defined multi-helix structure that optimizes translation; in MASH, hepatic IL-1β inhibits A1AT transcription through HNF4α, disinhibiting PR3-mediated cleavage of IL-32γ to drive liver inflammation and fibrosis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SERPINA1 (A1AT) is a secreted serine protease inhibitor whose canonical function is the neutralization of neutrophil elastase through a reactive-center loop centered on Met358 displayed on an external stressed loop, with two salt bridges (Glu342-Lys290; Glu263-Lys387) stabilizing the native fold [#0]. Disruption of these stabilizing interactions by natural missense variants causes intracellular polymerization and secretion failure: numerous variants form ER polymers and fail to secrete, while the Z (Glu342Lys) substitution drives polymer assembly that can incorporate wild-type M subunits into heteropolymers in vivo [#11, #10]. This toxic hepatocyte polymer burden is cleared through autophagy/lysosomal degradation, and forced TFEB expression promotes autolysosomal polymer clearance while lowering monomer expression [#7]. Beyond protease inhibition, A1AT exerts elastase-inhibitory-independent activities: native and oxidized forms equally inhibit caspase-3/caspase-8 and reduce ADAM17/TACE activity to limit hepatocyte apoptosis [#6], and it suppresses macrophage iNOS expression and NF-\\u03baB activation to dampen NO production [#13]. A1AT also acts as a hepatocyte-derived signaling ligand, complexing with the EphB2 receptor to drive preadipocyte proliferation, adipose browning, and UCP1-dependent thermogenesis [#17], inhibiting RANKL-induced osteoclastogenesis by suppressing RANK and DC-STAMP [#14], and promoting chondrogenic differentiation through PKA/CREB and Wnt/\\u03b2-catenin signaling [#15]. Circulating A1AT reaches the lung epithelium by active transcytosis across pulmonary endothelium, with SR-BI serving as a key endocytic receptor via clathrin- and caveolae-mediated uptake [#4, #5]. Its expression is tuned at multiple levels, including NQO1 binding to the SERPINA1 3'UTR to promote translation [#8], a defined multi-helix 5'-UTR structure that optimizes translation initiation [#9], and transcriptional repression by IL-1\\u03b2 via HNF4\\u03b1 in metabolic liver disease, where loss of A1AT disinhibits proteinase-3-mediated cleavage of IL-32\\u03b3 to drive inflammation and fibrosis [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Established the molecular basis of protease inhibition and protein stability, defining the active-site residue and the salt bridges whose disruption causes disease variants.\",\n      \"evidence\": \"Structural and biochemical characterization of natural protein variants\",\n      \"pmids\": [\"3289385\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address non-canonical (elastase-independent) functions\", \"Mechanism of polymer assembly not resolved at this stage\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Determined that A1AT is N-glycosylated on three asparagines during secretion, clarifying post-translational processing in the secretory pathway.\",\n      \"evidence\": \"Recombinant expression in yeast with endoglycosidase H treatment\",\n      \"pmids\": [\"3315863\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Yeast glycosylation differs from human; in vivo human glycan structure not defined here\", \"Functional consequence of glycosylation not tested\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Extended A1AT expression beyond hepatocytes to intestinal enterocytes and Paneth cells, indicating local production at mucosal surfaces.\",\n      \"evidence\": \"In situ hybridization and double-label immunohistochemistry of human gut\",\n      \"pmids\": [\"8408656\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of intestinal A1AT not established\", \"Relative contribution to systemic A1AT pool unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified mammary gland expression and milk A1AT, with a protease-protective role suggesting a function in protecting milk proteins during digestion.\",\n      \"evidence\": \"RT-PCR, milk ELISA, in vitro pepsin/pancreatin digestion assays\",\n      \"pmids\": [\"12324297\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance to infant nutrition not demonstrated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed an elastase-independent anti-inflammatory mechanism whereby A1AT suppresses macrophage NO production through iNOS and NF-\\u03baB inhibition.\",\n      \"evidence\": \"Macrophage stimulation assays plus exhaled NO in AAT-deficient subjects\",\n      \"pmids\": [\"22975343\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular target upstream of NF-\\u03baB not identified\", \"Receptor mediating macrophage uptake not defined here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed that boosting autophagy/lysosomal biogenesis via TFEB clears toxic Z polymer, defining a degradation route for misfolded intracellular A1AT.\",\n      \"evidence\": \"Liver-directed TFEB gene transfer in a SERPINA1 deficiency mouse model\",\n      \"pmids\": [\"23584152\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Selectivity of polymer vs monomer clearance not fully dissected\", \"Long-term efficacy and safety not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that A1AT inhibits caspase-3/8 and ADAM17 independently of elastase inhibition, establishing a cytoprotective antiapoptotic role.\",\n      \"evidence\": \"Cell-free caspase assays and mouse acute liver failure models with native vs oxidized A1AT\",\n      \"pmids\": [\"24449466\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mode of caspase inhibition (direct vs indirect) not structurally resolved\", \"Intracellular access of extracellular A1AT to caspases not fully explained\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that A1AT is actively transcytosed across pulmonary endothelium, explaining how circulating A1AT reaches lung epithelium.\",\n      \"evidence\": \"Confocal time-lapse, transwell co-culture, and intravital microscopy with tunicamycin\",\n      \"pmids\": [\"24743137\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor not yet identified at this stage\", \"Quantitative contribution to alveolar A1AT unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified SR-BI as a key endocytic receptor mediating A1AT uptake by pulmonary endothelium via clathrin- and caveolae-dependent routes.\",\n      \"evidence\": \"EM of gold-labeled A1AT, SR-BI Co-IP, siRNA, neutralizing antibody, Scarb1 KO mice\",\n      \"pmids\": [\"26092999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Residual 50-70% uptake implies additional receptors\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Uncovered translational control of A1AT by NQO1 binding the SERPINA1 3'UTR, linking redox status to A1AT protein output.\",\n      \"evidence\": \"RIP-microarray, biotin pulldown, polysome profiling, luciferase reporter, NQO1-KO mice\",\n      \"pmids\": [\"27515817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise NQO1 binding element not mapped\", \"Mechanistic coupling to ribosome loading not structurally defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Characterized A1AT as an inhibitor of RANKL-driven osteoclastogenesis through suppression of RANK and DC-STAMP, expanding its role to bone remodeling.\",\n      \"evidence\": \"In vitro osteoclast differentiation, receptor and gene expression, resorption assays\",\n      \"pmids\": [\"28332697\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating A1AT effect on osteoclast precursors unknown\", \"No in vivo bone phenotype shown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified a negative feedback loop in which exogenous A1AT lowers its own SERPINA1 mRNA in hepatocytes and PBMCs.\",\n      \"evidence\": \"Dose-response treatment of primary human hepatocytes and PBMCs with qRT-PCR\",\n      \"pmids\": [\"28486562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway mediating autoregulation not defined\", \"Relevance to augmentation therapy dosing unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed that carbamylated A1AT is an autoantigen recognized by anti-CarP antibodies in rheumatoid arthritis, linking A1AT modification to autoimmunity.\",\n      \"evidence\": \"Ion exchange fractionation, mass spectrometry, ELISA, synovial fluid detection\",\n      \"pmids\": [\"28291659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pathogenic role of anti-Ca-A1AT antibodies not established\", \"Carbamylation site stoichiometry in vivo unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Functionally classified novel missense variants by polymerization and secretion behavior, refining genotype-to-pathology relationships.\",\n      \"evidence\": \"HEK293T overexpression with PAS staining, pulse-chase, elastase assays\",\n      \"pmids\": [\"29232161\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression system may not reflect endogenous folding kinetics\", \"Clinical penetrance of variants not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided direct structural evidence that wild-type M A1AT is incorporated into Z polymers in vivo, demonstrating heteropolymerization.\",\n      \"evidence\": \"Antibody epitope crystallography and negative-stain EM of Fab-labeled liver-explant polymers\",\n      \"pmids\": [\"32699193\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full polymer interface structure not solved\", \"Functional consequence of M incorporation for MZ carriers not quantified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined how A1AT deficiency dysregulates neutrophil degranulation via Rac2/PAR2/ROS, and showed augmentation therapy normalizes the membrane proteome.\",\n      \"evidence\": \"Neutrophil membrane proteomics, FRET, ELISA, in vivo augmentation cohort\",\n      \"pmids\": [\"32060059\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct A1AT target in the Rac2/PAR2 axis not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established A1AT as a promoter of chondrogenic differentiation acting through PKA/CREB activation and Wnt/\\u03b2-catenin inhibition.\",\n      \"evidence\": \"SERPINA1 transfection and recombinant protein in human chondrocytes with pathway and gene analysis plus arthritis models\",\n      \"pmids\": [\"33788977\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor transducing the chondrocyte signal unknown\", \"Direct vs indirect pathway engagement unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked SERPINA1 to placental biology and preterm birth through cytoskeletal/Slit-Robo/ECM pathway regulation in trophoblasts and human genetic data.\",\n      \"evidence\": \"siRNA knockdown with pathway analysis, whole exome sequencing, placental proteomics\",\n      \"pmids\": [\"35477570\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting A1AT to actin/Slit-Robo regulation unclear\", \"Causality of rare variants not functionally proven\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified A1AT as a hepatocyte-derived EphB2 ligand controlling adipose browning and systemic metabolism, a receptor-mediated signaling role.\",\n      \"evidence\": \"Liver-specific transgenic and KO mice, EphB2 Co-IP, adipocyte assays, metabolic phenotyping\",\n      \"pmids\": [\"39532838\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of A1AT-EphB2 interaction not solved\", \"Whether protease-inhibitory activity is required not determined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Positioned A1AT in a MASH circuit where IL-1\\u03b2/HNF4\\u03b1 represses A1AT, disinhibiting PR3 cleavage of IL-32\\u03b3 to drive liver inflammation and fibrosis.\",\n      \"evidence\": \"Quintuple Serpina1 KO mice, cleavage-resistant IL-32\\u03b3 mutant, HNF4\\u03b1 analysis, in vivo A1AT restoration\",\n      \"pmids\": [\"39939782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct HNF4\\u03b1 binding at the SERPINA1 promoter not structurally mapped\", \"Translation of PR3 inhibition to human MASH not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How A1AT's diverse receptor-mediated and protease-independent signaling functions are integrated, and which require versus do not require its protease-inhibitory activity, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model linking elastase inhibition, EphB2 binding, and caspase inhibition\", \"Receptors for several non-canonical effects (chondrocyte, osteoclast) unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 6, 14]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [7, 11]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 16]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 10, 11, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [17, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"EphB2\", \"SCARB1\", \"NQO1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}